Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma

This publication has 16 references indexed in Scilit:

• Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
  Journal of Hepatology, 2022
• Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
  The Lancet Oncology, 2021
• NASH limits anti-tumour surveillance in immunotherapy-treated HCC
  Nature, 2021
• Association of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer
  International Journal of Molecular Sciences, 2021
• Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
  New England Journal of Medicine, 2020
• Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer
  JAMA Oncology, 2020
• The Surprisingly Positive Association Between Obesity and Cancer Immunotherapy Efficacy
  JAMA, 2019
• Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
  Nature Medicine, 2018
• Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
  The Lancet Oncology, 2018
• The global obesity pandemic: shaped by global drivers and local environments
  The Lancet, 2011